Complaints To CDER Down, But Lorcaserin Weighs Heavily At Ombudsman's Office
Executive Summary
Investors in Arena Pharmaceuticals and others angered by an advisory panel vote last September against approving the company's obesity drug Lorqess (lorcaserin) sent 467 complaints to the CDER Ombudsman's Office.
You may also be interested in...
Small Companies Turning To CDER Ombudsman For Help With Drug Approvals
While the CDER ombudsman dealt with far fewer complaints overall in 2011 than in 2010 due to administrative changes, smaller companies are increasingly asking for help in certain key areas of drug development.
Panel Continues To Push For Obesity CV Guidance As It Backs Contrave Approval
FDA signaled during an advisory committee on Orexigen's weight-loss drug Contrave that it could be ready to revise its obesity drug draft guidance, particularly with regard to cardiovascular goals, but stressed that for now, the drugs under review are to be judged by standards articulated in the draft document.
Selective Trial Populations Weigh Against Advisory Panel Support For Lorqess
Committee votes 9 to 5 vote against approval of Arena's weight loss drug, troubled that the study populations didn't reflect the real world.